Reduced red blood cell velocity in nail-fold capillaries as a sensitive and specific indicator of microcirculation injury in systemic sclerosis

Rheumatology

Volumn 48, Issue 6, 2009, Pages 696-703

  Mugii, Naoki ^a   Hasegawa, Minoru ^b   Hamaguchi, Yasuhito ^b   Tanaka, Chihiro ^b   Kaji, Kenzo ^b   Komura, Kazuhiro ^b   Ueda Hayakawa, Ikuko ^b   Horie, Sho ^a   Ikuta, Munehiro ^b   Tachino, Katsuhiko ^b   Ogawa, Fumihide ^c   Sato, Shinichi ^c   Fujimoto, Manabu ^b   Takehara, Kazuhiko ^b  

^a KANAZAWA UNIVERSITY HOSPITAL   (Japan)

^b KANAZAWA UNIVERSITY   (Japan)

^c NAGASAKI UNIVERSITY   (Japan)

Author keywords

Capillaroscopy; Digital ulcer; Lipo prostaglandin E1; Red blood cell velocity; Systemic sclerosis

Indexed keywords

ACETYLSALICYLIC ACID; BERAPROST; BOSENTAN; COLLAGEN; LIPOPROSTAGLANDIN E1; PREDNISOLONE; SARPOGRELATE; WARFARIN;

ADULT; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; BLOOD FLOW VELOCITY; CAPILLAROSCOPY; CAPILLARY FLOW; COLLAGEN DISEASE; CONTROLLED STUDY; DERMATOMYOSITIS; DISEASE DURATION; ERYTHROCYTE; FEMALE; FINGER NAIL; HUMAN; MAJOR CLINICAL STUDY; MALE; MICROCIRCULATION; POLYMYOSITIS; PRIORITY JOURNAL; RAYNAUD PHENOMENON; RHEUMATOID ARTHRITIS; SCLERODERMA; SENSITIVITY AND SPECIFICITY; SKIN ULCER; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS;

AGED; BLOOD FLOW VELOCITY; CAPILLARIES; ERYTHROCYTES; FEMALE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MALE; MICROCIRCULATION; MICROSCOPIC ANGIOSCOPY; MIDDLE AGED; NAILS; SCLERODERMA, SYSTEMIC; SENSITIVITY AND SPECIFICITY;

EID: 65849465285     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kep066     Document Type: Article

References (52)

1. Denton CP, Black CM. Targeted therapy comes of age in scleroderma. Trends Immunol 2005;26:596-602.
2. Charles C, Clements P, Furst DE. Systemic sclerosis: Hypothesis-driven treatment strategies. Lancet 2006;367:1683-91.
3. Varga J, Abraham D. Systemic sclerosis: A prototypic multisystem fibrotic disorder. J Clin Invest 2007;117:557-67.
4. LeRoy EC. Systemic sclerosis. A vascular perspective. Rheum Dis Clin North Am 1996;22:675-94.
5. Maricq HR, LeRoy EC. Patterns of finger capillary abnormalities in connective tissue disease by "wide-field" microscopy. Arthritis Rheum 1973;16:619-28.
6. Maricq HR. Wide-field capillary microscopy. Arthritis Rheum 1981;24:1159-65.
7. Redisch W, Messina EJ, Hughes G, McEwen C. Capillaroscopic observations in rheumatic diseases. Ann Rheum Dis 1970;29:244-53.
8. Cutolo M, Grassi W, Matucci Cerinic M. Raynaud's phenomenon and the role of capillaroscopy. Arthritis Rheum 2003;48:3023-30.
9. Ingegnoli F, Boracchi P, Gualtierotti R et al. Prognostic model based on nailfold capillaroscopy for identifying Raynaud's phenomenon patients at high risk for the development of a scleroderma spectrum disorder: PRINCE (Prognostic Index for Nailfold Capillaroscopic Examination). Arthritis Rheum 2008;58:2174-82.
10. Sulli A, Secchi ME, Pizzorni C, Cutolo M. Scoring the nailfold microvascular changes during the capillaroscopic analysis in systemic sclerosis patients. Ann Rheum Dis 2008;67:885-7.
11. Blockmans D, Beyens G, Verhaeghe R. Predictive value of nailfold capillaroscopy in the diagnosis of connective tissue diseases. Clin Rheumatol 1996;15:148-53.
12. Minkin W, Rabhan NB. Office nail fold capillary microscopy using ophthalmoscope. J Am Acad Dermatol 1982;7:190-3.
13. Vayssairat M. Preventive effect of an oral prostacyclin analog, beraprost sodium, on digital necrosis in systemic sclerosis. French Microcirculation Society Multicenter Group for the Study of Vascular Acrosyndromes. J Rheumatol 1999;26:2173-78.
14. Chung L, Fiorentino D. Digital ulcers in patients with systemic sclerosis. Autoimmun Rev 2006;5:125-8.
15. Martin MF, Dowd PM, Ring EF, Cooke ED, Dieppe PA, Kirby JD. Prostaglandin E1 infusions for vascular insufficiency in progressive systemic sclerosis. Ann Rheum Dis 1981;40:350-4.
16. Butti P, Intaglietta M, Reimann H, Holliger C, Bollinger A, Anliker M. Capillary red blood cell velocity measurements in human nailfold by videodensitometric method. Microvasc Res 1975;10:220-7.
17. Fagrell B, Fronek A, Intaglietta M. A microscope-television system for studying flow velocity in human skin capillaries. Am J Physiol 1977;233:H318-21.
18. Hahn M, Heubach T, Steins A, Junger M. Hemodynamics in nailfold capillaries of patients with systemic scleroderma: Synchronous measurements of capillary blood pressure and red blood cell velocity. J Invest Dermatol 1998;110:982-5.
19. Carlson LA, Olsson AG. Intravenous prostaglandin E1 in severe peripheral vascular disease. Lancet 1976;2:810.
20. Martin MF, Tooke JE. Effects of prostaglandin E1 on microvascular haemodynamics in progressive systemic sclerosis. Br Med J (Clin Res Ed) 1982;285:1688-90.
21. Salganicoff L, Russo MA. An hypothesis on the consolidation and PGE1-induced deconsolidation of a platelet plug. Platelets 2003;14:463-71.
22. Committee SfSCotARADaTC. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980;23:581-90.
23. LeRoy EC, Krieg T, Black C et al. Scleroderma (systemic sclerosis): Classification, subsets, and pathogenesis. J Rheumatol 1988;15:202-5.
24. Clements PJ, Lachenbruch PA, Seibold JR et al. Skin thickness score in systemic sclerosis: An assessment of interobserver variability in 3 independent studies. J Rheumatol 1993;20:1892-6.
25. Steen VD, Powell DL, Medsger TAJ. Clinical correlations and prognosis based on serum autoantibodies in patients with systemic sclerosis. Arthritis Rheum 1988;31:196-203.
26. Maricq HR, LeRoy EC, D'Angelo WA et al. Diagnostic potential of in vivo capillary microscopy in scleroderma and related disorders. Arthritis Rheum 1980;23:183-9.
27. Carpentier PH, Maricq HR. Microvasculature in systemic sclerosis. Rheum Dis Clin North Am 1990;16:75-91.
28. Beltran E, Toll A, Pros A, Carbonell J, Pujol RM. Assessment of nailfold capillaroscopy by x30 digital epiluminescence (dermoscopy) in patients with Raynaud phenomenon. Br J Dermatol 2007;156:892-8.
29. Bergman R, Sharony L, Schapira D, Nahir MA, Balbir-Gurman A. The handheld dermatoscope as a nail-fold capillaroscopic instrument. Arch Dermatol 2003; 139:1027-30.
30. Cutolo M, Sulli A, Pizzorni C, Accardo S. Nailfold videocapillaroscopy assessment of microvascular damage in systemic sclerosis. J Rheumatol 2000;27:155-60.
31. Kahaleh MB, Sherer GK, LeRoy EC. Endothelial injury in scleroderma. J Exp Med 1979;149:1326-35.
32. Zamora MR, O'Brien RF, Rutherford RB, Weil JV. Serum endothelin-1 concentrations and cold provocation in primary Raynaud's phenomenon. Lancet 1990; 336:1144-7.
33. Simeon CP, Fonollosa V, Vilardell M et al. Study of the capillary microscopy changes in scleroderma and their association with organ disease, clinical manifestations and disease progression. Med Clin 1991;97:561-4.
34. Chen ZY, Silver RM, Ainsworth SK, Dobson RL, Rust P, Maricq HR. Association between fluorescent antinuclear antibodies, capillary patterns, and clinical features in scleroderma spectrum disorders. Am J Med 1984;77:812-22.
35. Andrade LE, Gabriel Junior A, Assad RL, Ferrari AJ, Atra E. Panoramic nailfold capillaroscopy: A new reading method and normal range. Semin Arthritis Rheum 1990;20:21-31.
36. Bredemeier M, Xavier RM, Capobianco KG et al. Nailfold capillary microscopy can suggest pulmonary disease activity in systemic sclerosis. J Rheumatol 2004; 31:286-94.
37. Lee P, Leung FY, Alderdice C, Armstrong SK. Nailfold capillary microscopy in the connective tissue diseases: A semiquantitative assessment. J Rheumatol 1983;10:930-8.
38. Statham BN, Rowell NR. Quantification of the nail fold capillary abnormalities in systemic sclerosis and Raynaud's syndrome. Acta Derm Venereol 1986;66:139-43.
39. Cutolo M, Pizzorni C, Tuccio M et al. Nailfold videocapillaroscopic patterns and serum autoantibodies in systemic sclerosis. Rheumatology 2004;43:719-26.
40. Guiducci S, Giacomelli R, Cerinic MM. Vascular complications of scleroderma. Autoimmun Rev 2007;6:520-3.
41. Kuwana M, Okazaki Y, Yasuoka H, Kawakami Y, Ikeda Y. Defective vasculogenesis in systemic sclerosis. Lancet 2004;364:603-10.
42. Distler JH, Gay S, Distler O. Angiogenesis and vasculogenesis in systemic sclerosis. Rheumatology 2006;45(Suppl. 3):iIi26-27.
43. Del Papa N, Quirici N, Soligo D et al. Bone marrow endothelial progenitors are defective in systemic sclerosis. Arthritis Rheum 2006;54:2605-15.
44. Cipriani P, Guiducci S, Miniati I et al. Impairment of endothelial cell differentiation from bone marrow-derived mesenchymal stem cells: new insight into the pathogenesis of systemic sclerosis. Arthritis Rheum 2007;56:1994-2004.
45. Kovacs IB, Sowemimo-Coker SO, Kirby JD, Turner P. Altered behaviour of erythrocytes in scleroderma. Clin Sci 1983;65:515-9.
46. Dowd PM, Kovacs IB, Bland CJ, Kirby JD. Effect of prostaglandins I2 and E1 on red cell deformability in patients with Raynaud's phenomenon and systemic sclerosis. Br Med J (Clin Res Ed) 1981;283:350.
47. Chino Y, Minagawa T, Kohno Y, Toda Y, Murakami S, Higuchi S. Uptake by vascular smooth muscle cells plays an important role in targeting of lipid microspheres incorporating prostaglandin E1 into a thickened intima. Life Sci 2001;68:933-42.
48. Clifford PC, Martin MF, Sheddon EJ, Kirby JD, Baird RN, Dieppe PA. Treatment of vasospastic disease with prostaglandin E1. Br Med J 1980;281:1031-4.
49. Langevitz P, Buskila D, Lee P, Urowitz MB. Treatment of refractory ischemic skin ulcers in patients with Raynaud's phenomenon with PGE1 infusions. J Rheumatol 1989;16:1433-5.
50. Filaci G, Cutolo M, Scudeletti M et al. Cyclosporin A and iloprost treatment of systemic sclerosis: Clinical results and interleukin-6 serum changes after 12 months of therapy. Rheumatology 1999;38:992-6.
51. Faggioli P, Giani L, Mazzone A. Possible role of iloprost (stable analog of PG12) in promoting neoangiogenesis in systemic sclerosis. Clin Exp Rheumatol 2006; 24:220-1.
52. Aschwanden M, Daikeler T, Jaeger KA et al. Rapid improvement of nailfold capillaroscopy after intense immunosuppression for systemic sclerosis and mixed connective tissue disease. Ann Rheum Dis 2008;67:1057-9.